What are the common specifications and dosage selection recommendations for Platinib (Pujihua) capsules?

Pralsetinib is an oral RET inhibitor, mainly used for the treatment of non-small cell lung cancer related to RET gene mutations and other RET-positive tumors. The drug is provided in capsule form, which is convenient for patients to take orally by themselves. It also facilitates doctors to adjust the dose individually based on the patient's weight, liver and kidney function, and tolerance.

In terms of specifications, platinib capsules are commonly available in two types: 100mg and 200mg. 100mgThe specification is suitable for patients who require a lower starting dose or those who need to gradually tolerate the drug in the early stages of medication; 200mgcapsules are suitable for the generally recommended dose or for patients who are heavier and have better tolerance. Drug instructions usually recommend selecting appropriate specifications based on the patient's specific conditions to ensure efficacy and reduce the risk of adverse reactions.

Regarding dosage selection, the recommended dose is 400 mg once daily. For patients with hepatic or renal impairment, doctors may adjust the starting dose based on specific circumstances, such as reducing it to 200 mg or gradually increasing it to the target dose. At the same time, if the patient experiences obvious adverse reactions during treatment, such as high blood pressure, hematological abnormalities, or gastrointestinal reactions, the dosage can be temporarily reduced or the medication suspended under the guidance of a doctor to ensure safety.

In clinical practice, individualized medication is particularly important. The doctor will select the appropriate capsule size and dosage plan based on the patient's weight, liver and kidney function, concomitant medications, and tolerance. Patients should strictly follow the doctor's recommendations and drug instructions when taking the medication, and avoid increasing or decreasing the dosage on their own. At the same time, blood routine and liver function should be reviewed regularly during the medication period to ensure the therapeutic effect and medication safety.

Reference materials:https://www.drugs.com/